Prophylaxis in congenital coagulation disorders: Past, present and future

Blood Transfusion

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Mannucci, Pier Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLOOD CLOTTING DISORDER; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; HUMAN; PROPHYLAXIS; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTORS; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; MALE; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASE;

EID: 56649084979     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0029-08     Document Type: Conference Paper

References (12)

1. Mannucci PM. Back to the future: a recent history of hemophilia treatment. Haemophilia 2008;14 (Suppl 3):10-9.
2. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965:issue(Suppl 77):3-132.
3. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
4. Ljung R. Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. Haemophilia 2007;13 (Suppl 2):1-3.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factar-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
7. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36.
8. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5:1904-13.
9. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006;32:621-5.
10. Berntorp E, Abshire T. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept. Thromb Res 2006;118 (Suppl 1):S19-S22.
11. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO.WILL study. Haemophilia 2007;13:15-24.
12. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-52.